SEARCH

SEARCH BY CITATION

References

  • 1
    Cheng A, Barriere S, Coakley DF, Chen SS, Wulfsohn M, Toole JJ. Safety profile of tenofovir DF in antiretroviral-experienced patients from randomized, double-blind, placebo-controlled clinical trials. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002 [Abstract 416-W].
  • 2
    Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral naive patients: a 3-year randomized trial. J Am Med Assoc 2004; 292: 191201.
  • 3
    Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 13311333.
  • 4
    Coca S, Perazella MA. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342344.
  • 5
    Karras A, Lafaurie M, Furco A et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 10701073.
  • 6
    Créput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17: 935937.
  • 7
    Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: e4143.
  • 8
    Rollot F, Nazal EM, Chauvelot-Moachon L et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003; 37: e174176.
  • 9
    Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 2003; 47: 262263.
  • 10
    Peyrière H, Reynes J, Rouanet I et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269273.
  • 11
    James CW, Steinhaus MC, Szabo S, Dressler RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004; 24: 415418.
  • 12
    Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004; 18: 960963.
  • 13
    Gaspar G, Monereo A, Garcia-Reyne A, De Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004; 18: 351352.
  • 14
    Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004; 117: 282284.
  • 15
    Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 16
    Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucl Acids 2001; 20: 641648.
  • 17
    Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJM. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antivir Res 2002; 54: 3745.
  • 18
    Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716723.
  • 19
    Gilead Sciences Inc. Viread (Tenofovir) Product Monograph. Foster City, CA: Gilead Sciences Inc., 2003.
  • 20
    Harris M, Yip B, Zalunardo N et al. Increases in creatinine during therapy with tenofovir DF. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, July 2003 [Abstract 55].
  • 21
    Flaherty J, Kearney B, Wolf J, Sayre J, Coakley D. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001 [Abstract 336].
  • 22
    Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383389.
  • 23
    Rajpopat S, Nelson M. Is there an increased risk of toxicity in individuals receiving combinations including Kaletra/tenofovir? 9th European AIDS Conference. Warsaw, Poland, October 2003 [Abstract 7.4/6].
  • 24
    Harris M, Zalunardo N, Bonner S, Werb R, Valyi M, Montaner JSG. Use of estimated glomerular filtration rate to predict renal toxicity in patients receiving tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 750].
  • 25
    Day S, Leake Date H, Hankins M, Bannister A, Fisher M. Hypophosphatemia in patients taking tenofovir. 9th European AIDS Conference. Warsaw, Poland, October 2003 [Abstract 9.7/4].
  • 26
    Roca B, Rovira RE, Cabestany B, Perez AP, Ventura JM, Ferrero JA. Renal function before and after tenofovir disoproxil fumarate. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Paris, France, July 2003 [Abstract L91].